Posted at January 7, 2015 7:14 pm by Jennifer Huron
Today, NORD Vice President Diane Dorman is providing remarks before the FDA Oncologic Drugs Advisory Committee on the importance of distinguishable names for biologics as a fundamental core of maximizing the benefits for patients and minimizing any potential harm from biosimilars. This is part of NORD’s work to provide advocacy on behalf of the entire rare disease community. Read Diane’s remarks here and follow the conversation online under the hashtag, #ODAC.
Posted at June 4, 2014 1:47 pm by Peter L Saltonstall
Biologic therapies have been lifesaving and life changing for the patients we represent – more than 30 million Americans with more than 7,000 rare diseases. Literally, hundreds of thousands of rare disease patients have found their lives bettered by biologics and we are collectively grateful to the innovators and companies that have made this possible. read more >